CorMedix (CRMD) News Today $10.13 -0.69 (-6.38%) Closing price 04:00 PM EasternExtended Trading$10.20 +0.07 (+0.70%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cormedix (NASDAQ:CRMD) Stock Quotes, Forecast and News SummaryFebruary 21 at 6:59 PM | benzinga.comCorMedix Inc. (NASDAQ:CRMD) Receives $15.67 Consensus Target Price from BrokeragesFebruary 15, 2025 | americanbankingnews.com126,015 Shares in CorMedix Inc. (NASDAQ:CRMD) Purchased by Wingate Wealth Advisors Inc.Wingate Wealth Advisors Inc. acquired a new stake in CorMedix Inc. (NASDAQ:CRMD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 126,015 shares of the company's stock, valued at approximatFebruary 10, 2025 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Receives Average Rating of "Buy" from BrokeragesShares of CorMedix Inc. (NASDAQ:CRMD - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target amoFebruary 10, 2025 | marketbeat.comCorMedix (NASDAQ:CRMD) Shares Down 3.7% - What's Next?CorMedix (NASDAQ:CRMD) Trading Down 3.7% - Time to Sell?January 29, 2025 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Position Raised by JPMorgan Chase & Co.JPMorgan Chase & Co. increased its position in shares of CorMedix Inc. (NASDAQ:CRMD - Free Report) by 685.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 194,108 shares of theJanuary 24, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for CorMedix (NASDAQ:CRMD)D. Boral Capital reaffirmed a "buy" rating and issued a $15.00 price target on shares of CorMedix in a research report on Wednesday.January 22, 2025 | marketbeat.comCorMedix announces collaboration with WSI PBG for DefenCathJanuary 21, 2025 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Shares Down 4.2% - Should You Sell?CorMedix (NASDAQ:CRMD) Shares Down 4.2% - Should You Sell?January 17, 2025 | marketbeat.comBarclays PLC Sells 84,122 Shares of CorMedix Inc. (NASDAQ:CRMD)Barclays PLC trimmed its holdings in CorMedix Inc. (NASDAQ:CRMD - Free Report) by 51.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,870 shares of the company's stock after selling 84,122 shares durinJanuary 17, 2025 | marketbeat.comCorMedix (NASDAQ:CRMD) Stock Price Up 6.1% - Here's WhyCorMedix (NASDAQ:CRMD) Stock Price Up 6.1% - Here's What HappenedJanuary 16, 2025 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Given Consensus Recommendation of "Buy" by BrokeragesCorMedix Inc. (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Buy" from the six research firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issuedJanuary 16, 2025 | marketbeat.comD. Boral Capital Initiates Coverage of CorMedix (CRMD) with Buy RecommendationJanuary 14, 2025 | msn.comCorMedix initiated with a Buy at D. Boral CapitalJanuary 13, 2025 | markets.businessinsider.comD. Boral Capital Initiates Coverage on CorMedix (NASDAQ:CRMD)D. Boral Capital assumed coverage on shares of CorMedix in a report on Monday. They issued a "buy" rating and a $15.00 price target for the company.January 13, 2025 | marketbeat.comRBC Capital Keeps Their Buy Rating on Cormedix (CRMD)January 10, 2025 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Stock Price Up 2.5% - Should You Buy?CorMedix (NASDAQ:CRMD) Trading Up 2.5% - Time to Buy?January 8, 2025 | marketbeat.comCormedix: Strong Financial Outlook and Strategic Growth Initiatives Support Buy RatingJanuary 8, 2025 | markets.businessinsider.comCorMedix, Inc.: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business UpdateJanuary 7, 2025 | finanznachrichten.deCormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth ProspectsJanuary 7, 2025 | markets.businessinsider.comCorMedix up 22% at $9.66 in pre-market after Q4 revenue pre-announcementJanuary 7, 2025 | markets.businessinsider.comCorMedix Shares Rise 21% After Preliminary 4Q Results Beat EstimatesJanuary 7, 2025 | marketwatch.comCorMedix: Finally In Commercialization ModeJanuary 7, 2025 | seekingalpha.comCorMedix stock soars on preliminary Q4 revenue beatJanuary 7, 2025 | in.investing.comCorMedix (NASDAQ:CRMD) Shares Gap Up - What's Next?CorMedix (NASDAQ:CRMD) Shares Gap Up - Still a Buy?January 7, 2025 | marketbeat.comCorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business UpdateJanuary 7, 2025 | globenewswire.comCorMedix Inc. (NASDAQ:CRMD) Receives Average Rating of "Buy" from AnalystsShares of CorMedix Inc. (NASDAQ:CRMD - Get Free Report) have earned an average rating of "Buy" from the five ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among anDecember 22, 2024 | marketbeat.comCorMedix's SWOT analysis: defencath launch boosts stock amid expansion plansDecember 21, 2024 | uk.investing.comCorMedix (NASDAQ:CRMD) Stock Price Down 2.6% - Should You Sell?CorMedix (NASDAQ:CRMD) Stock Price Down 2.6% - Should You Sell?December 20, 2024 | marketbeat.comCorMedix price target raised to $12 from $11 at RBC CapitalDecember 20, 2024 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Stock Price Up 5.9% Following Analyst UpgradeCorMedix (NASDAQ:CRMD) Stock Price Up 5.9% After Analyst UpgradeDecember 19, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Price Target Raised to $12.00Royal Bank of Canada lifted their price objective on CorMedix from $11.00 to $12.00 and gave the stock an "outperform" rating in a report on Thursday.December 19, 2024 | marketbeat.comCorMedix Inc. Added to Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comWellington Management Group LLP Acquires 102,527 Shares of CorMedix Inc. (NASDAQ:CRMD)Wellington Management Group LLP grew its holdings in CorMedix Inc. (NASDAQ:CRMD - Free Report) by 130.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 180,948 shares of the company's stock after purchasing an additional 102,527 shares duringDecember 19, 2024 | marketbeat.comIs CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?December 19, 2024 | insidermonkey.comErin Mistry Acquires 1,500 Shares of CorMedix Inc. (NASDAQ:CRMD) StockDecember 14, 2024 | insidertrades.comCorMedix Inc. (NASDAQ:CRMD) EVP Purchases $14,985.00 in StockCorMedix Inc. (NASDAQ:CRMD - Get Free Report) EVP Erin Mistry purchased 1,500 shares of the firm's stock in a transaction that occurred on Thursday, October 31st. The stock was purchased at an average price of $9.99 per share, with a total value of $14,985.00. Following the completion of the purchase, the executive vice president now directly owns 52,011 shares of the company's stock, valued at approximately $519,589.89. This represents a 2.97 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.December 13, 2024 | marketbeat.comParallax Volatility Advisers L.P. Buys New Shares in CorMedix Inc. (NASDAQ:CRMD)Parallax Volatility Advisers L.P. purchased a new position in shares of CorMedix Inc. (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 80,143 shares of the company's stock, valued at approximateDecember 7, 2024 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Given Average Recommendation of "Buy" by BrokeragesShares of CorMedix Inc. (NASDAQ:CRMD - Get Free Report) have earned a consensus recommendation of "Buy" from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target amNovember 27, 2024 | marketbeat.comCorMedix supports CMS policy updatesNovember 26, 2024 | markets.businessinsider.comCorMedix Set for Market Growth with Policy Changes and Strategic Partnerships Boosting DefenCath AdoptionNovember 26, 2024 | markets.businessinsider.comCorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug ProductsNovember 26, 2024 | globenewswire.comCorMedix Inc. (NASDAQ:CRMD) EVP Elizabeth Hurlburt Sells 140,027 SharesNovember 19, 2024 | insidertrades.comCorMedix Inc. (NASDAQ:CRMD) Short Interest Down 20.1% in OctoberCorMedix Inc. (NASDAQ:CRMD - Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 6,280,000 shares, a decline of 20.1% from the October 15th total of 7,860,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 5.4 days.November 15, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Stock Price Up 8.9% - Should You Buy?CorMedix (NASDAQ:CRMD) Trading 8.9% Higher - Here's What HappenedNovember 8, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Upgraded to Sell at StockNews.comStockNews.com raised CorMedix to a "sell" rating in a research note on Friday.November 8, 2024 | marketbeat.comCorMedix Inc. to Participate in the Truist Securities BioPharma SymposiumNovember 4, 2024 | globenewswire.comRainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More OptimisticNovember 4, 2024 | finance.yahoo.comCorMedix Inc. (NASDAQ:CRMD) Receives Average Recommendation of "Buy" from BrokeragesCorMedix Inc. (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Buy" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analyNovember 2, 2024 | marketbeat.comWhile shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunateNovember 1, 2024 | finance.yahoo.com Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Media Mentions By Week CRMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRMD News Sentiment▼0.000.60▲Average Medical News Sentiment CRMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRMD Articles This Week▼13▲CRMD Articles Average Week Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IBRX News ARWR News HCM News EWTX News MIRM News AMRX News KYMR News GMTX News PTGX News MESO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRMD) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
